Correction: Safety and feasibility of intravenous administration of a single dose of allogenic-Muse cells to treat human cervical traumatic spinal cord injury: a clinical trial

MLA

Masao Koda, et al. “Correction: Safety and Feasibility of Intravenous Administration of a Single Dose of Allogenic-Muse Cells to Treat Human Cervical Traumatic Spinal Cord Injury: A Clinical Trial.” Stem Cell Research & Therapy, vol. 15, no. 1, Nov. 2024, p. 1. EBSCOhost, https://doi.org/10.1186/s13287-024-04044-0.

APA

Masao Koda, Shiro Imagama, Hiroaki Nakashima, Sadayuki Ito, Naoki Segi, Jun Ouchida, Kota Suda, Satoko Harmon Matsumoto, Miki Komatsu, Toshiki Endo, Shinsuke Suzuki, Satoshi Inami, Haruki Ueda, Masayuki Miyagi, Gen Inoue, Masashi Takaso, Keiji Nagata, Hiroshi Yamada, Naosuke Kamei, … Masashi Yamazaki. (2024). Correction: Safety and feasibility of intravenous administration of a single dose of allogenic-Muse cells to treat human cervical traumatic spinal cord injury: a clinical trial. Stem Cell Research & Therapy, 15(1), 1. https://doi.org/10.1186/s13287-024-04044-0

Chicago

Masao Koda, Shiro Imagama, Hiroaki Nakashima, Sadayuki Ito, Naoki Segi, Jun Ouchida, Kota Suda, et al. 2024. “Correction: Safety and Feasibility of Intravenous Administration of a Single Dose of Allogenic-Muse Cells to Treat Human Cervical Traumatic Spinal Cord Injury: A Clinical Trial.” Stem Cell Research & Therapy 15 (1): 1. doi:10.1186/s13287-024-04044-0.